Cardiovascular Outcomes in Randomized Trials. Should Time to First Event for "Hard" End Points Remain the Standard Approach?

Journal of the American College of Cardiology

Volumn 54, Issue 25, 2009, Pages 2363-2365

  Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

heart failure; hemodynamic; pacing site; resynchronization

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; PRAVASTATIN;

ACUTE CORONARY SYNDROME; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; CHOLESTEROL; ENDPOINT DETERMINATION; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL REVASCULARIZATION; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE; TIME FACTORS;

EID: 71649097137     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.09.021     Document Type: Editorial

References (4)

1. Murphy S.A., Cannon C.P., Wiviott S.D., McCabe C.H., and Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 54 (2009) 2358-2362
2. Tikkanen M.J., Szarek M., Fayyad R., et al., IDEAL Investigators. Total cardiovascular disease burden: comparing intensive with moderate statin therapy: insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 54 (2009) 2353-2357
3. Grundy S.M., Cleeman J.I., Merz C.N., et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
4. Dormandy J.A., Charbonnel B., Eckland D.J., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289